ArticleACS omega2025
Microwave-Assisted Transesterification of Enriched Crude Glycerol to Glycerol Carbonate: Optimization, Simulation, and Techno-Economic Evaluation.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research presents a novel approach to create glycerol carbonate (GC) from refined crude glycerol through microwave-assisted transesterification. It integrates experimental enhancement with techno-economic and ecological assessments. The refining procedure raised the glycerol content from 40.56 wt % to 98.83 wt %, ensuring a high-quality input. Response surface methodology (RSM) was used to aid optimization of the reaction conditions. The best conditions were a 6.5 wt % catalyst concentration, 2.74:1 dimethyl carbonate:glycerol molar ratio, a reaction temperature of 78.36 °C, and a reaction duration of 36.5 min, which gave a 73.65% yield of GC. Experimental data matched the model estimates under these settings, validating the RSM dependability. The activation energy was calculated as 54.57 kJ/mol. A techno-economic assessment, performed using the Aspen Plus V11 software, revealed that the process is a viable investment possibility, with a net present value of $31.23 million, an internal rate of return of 27.96%, and a payback duration of 4.11 years. A sensitivity assessment revealed that the GC selling price considerably affected the profit and that the CO
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.